Large Intestine

Despite advances in treatment over the last 50 years, metabolic diseases in general, and Type 2 Diabetes in particular, continue to be a principal and rapidly growing driver of morbidity and mortality in the 21st century. We are relentless in our commitment to change the trajectory of this large and growing burden carried by individuals, families, the healthcare systems, and governments around the world. We intend to accomplish this by developing therapies that prevent and eliminate metabolic disease.

Revita System


The Revita DMR system, or Revita®, our lead product candidate, is designed to remodel the duodenal lining via hydrothermal ablation in order to edit abnormal intestinal nutrient sensing and signaling mechanisms that we believe are a root cause of metabolic diseases.

Learn About Revita


We are developing Rejuva, a novel pancreatic gene therapy platform, to enable long-term remission of T2D by potentially restoring insulin production in patients with advanced disease.

Learn about Rejuva

You are now leaving the website

You are leaving Fractyl’s main website to go to Fractyl’s U.K. site.

By selecting Continue you will be directed to Fractyl’s U.K. site. If you would like to remain on Fractyl’s main site, select the Cancel button.